☆ 4.7 Meeting Abstract

Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 39, Issue 3, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2021.39.3_suppl.320

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.